{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:10:45Z","timestamp":1781115045977,"version":"3.54.1"},"reference-count":28,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The alternate day and the intermittent regimens of isotretinoin are efficacious in treating moderate acne vulgaris with low cumulative doses. The former regimen has been found to be superior in comparative studies using weight-based dosing. The fixed dosing of the two regimens has not been explored in a head-to-head trial. The objective was to compare the efficacy and safety of these regimens at fixed dosages in treating grade 2 facial acne vulgaris.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>It was a randomised, single-blinded, non-inferiority trial. Sixty patients aged 18 years and above with grade 2 facial acne were randomised into two groups: Group A received 20 mg isotretinoin on alternate days, and Group B received 30 mg daily for one wk per month for four months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean acne load in group A and B reduced to 5.63\u00b14.87 and 5.63\u00b14.87 from 22.60\u00b110 and 28.70\u00b118.10, respectively. The percentage of participants achieving a significant response was 96.7% and 93.3% in group A and B (\n                      <jats:italic>P=<\/jats:italic>\n                      0.28). The estimates were within the non-inferiority margins. The acne load progressively decreased with greater effect size as the treatment continued. Relapse to pretreatment score was not detected. Side effects were comparable between the groups. The cost was significantly higher with the alternate regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>The daily intermittent regimen is non-inferior to alternate day regimen at fixed dosages in significantly improving grade 2 facial acne vulgaris with similar side effect profiles. The daily intermittent regimen, also with a lower cost, is thus preferrable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_2458_2025","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:17:58Z","timestamp":1780312678000},"page":"731-737","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous alternate day\n                    <i>vs<\/i>\n                    intermittent daily fixed doses of oral isotretinoin in grade 2 acne vulgaris"],"prefix":"10.25259","volume":"163","author":[{"given":"Chingshubam","family":"Bikash","sequence":"first","affiliation":[{"name":"Department of Dermatology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Marak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"10.25259\/IJMR_2458_2025\/ref-1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol."},{"key":"10.25259\/IJMR_2458_2025\/ref-2","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1067\/mjd.2001.113717","article-title":"Uses and complications of isotretinoin therapy","volume":"45","author":"Ellis","year":"2001","journal-title":"J Am Acad Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-3","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: A randomized, controlled comparative study","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jaad.2005.11.1061","article-title":"Low-dose isotretinoin in the treatment of acne vulgaris","volume":"54","author":"Amichai","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-5","first-page":"291","article-title":"Comparison of efficacy of fixed low-dose regimens (daily vs alternate day) of oral isotretinoin in mild to moderate acne vulgaris","volume":"25","author":"Niazi","year":"2016","journal-title":"J Pak Assoc Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1365-4632.2012.05853.x","article-title":"Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris","volume":"52","author":"Boyraz","year":"2013","journal-title":"Int J Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0378-6323.58672","article-title":"Efficacy of low-dose isotretinoin in acne vulgaris","volume":"76","author":"Sardana","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"10.25259\/IJMR_2458_2025\/ref-8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00403-007-0777-2","article-title":"Treatment of acne with intermittent and conventional isotretinoin: A randomized, controlled multicenter study","volume":"299","author":"Akman","year":"2007","journal-title":"Arch Dermatol Res."},{"key":"10.25259\/IJMR_2458_2025\/ref-9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/jvc2.154","article-title":"A systematic review of isotretinoin dosing in acne vulgaris","volume":"2","author":"Daly","year":"2023","journal-title":"JEADV Clinical Practice."},{"key":"10.25259\/IJMR_2458_2025\/ref-10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4103\/0378-6323.86482","article-title":"Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial","volume":"77","author":"Agarwal","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"10.25259\/IJMR_2458_2025\/ref-11","first-page":"291","article-title":"Comparison of efficacy of fixed low-dose regimens (daily vs alternate day) of oral isotretinoin in mild to moderate acne vulgaris","volume":"25","author":"Niazi","year":"2016","journal-title":"J Pak Assoc Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-12","first-page":"S3","article-title":"The use of isotretinoin in the treatment of acne vulgaris: Clinical considerations and future directions","volume":"7","author":"Leyden","year":"2014","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/ada.2017.65614","article-title":"The use of isotretinoin in low doses and unconventional treatment regimens in different types of acne: A literature review","volume":"34","author":"Torzecka","year":"2017","journal-title":"Postepy Dermatol Alergol."},{"key":"10.25259\/IJMR_2458_2025\/ref-14","doi-asserted-by":"publisher","first-page":"2540594","DOI":"10.1080\/09546634.2025.2540594","article-title":"Levels of several inflammatory cytokines in acne patients before and after isotretinoin therapy: A randomized, controlled clinical trial","volume":"36","author":"Qi","year":"2025","journal-title":"J Dermatolog Treat."},{"key":"10.25259\/IJMR_2458_2025\/ref-15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamadermatol.2024.5416","article-title":"Acne relapse and isotretinoin retrial in patients with acne","volume":"161","author":"Lai","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-16","doi-asserted-by":"publisher","first-page":"e15974","DOI":"10.1111\/dth.15974","article-title":"Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study","volume":"35","author":"Kassem","year":"2022","journal-title":"Dermatol Ther."},{"key":"10.25259\/IJMR_2458_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/j.1468-3083.2006.01784.x","article-title":"The effectiveness of intermittent isotretinoin treatment in mild or moderate acne","volume":"20","author":"Kaymak","year":"2006","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.25259\/IJMR_2458_2025\/ref-18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1468-3083.2008.03022.x","article-title":"Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris","volume":"23","author":"Sardana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.25259\/IJMR_2458_2025\/ref-19","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2147\/DDDT.S427530","article-title":"Oral isotretinoin and its uses in dermatology: A review","volume":"17","author":"Paichitrojjana","year":"2023","journal-title":"Drug Des Devel Ther."},{"key":"10.25259\/IJMR_2458_2025\/ref-20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.53350\/pjmhs22164116","article-title":"Efficacy of low dose oral isotretinoin on alternate day Vs pulses regimen for acne vulgaris treatment: RCT","volume":"16","author":"Dawood","year":"2022","journal-title":"PJMHS."},{"key":"10.25259\/IJMR_2458_2025\/ref-21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: Understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials."},{"key":"10.25259\/IJMR_2458_2025\/ref-22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/2229-5178.190505","article-title":"A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris","volume":"7","author":"Dhaked","year":"2016","journal-title":"Indian Dermatol Online J."},{"key":"10.25259\/IJMR_2458_2025\/ref-24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/bcp.13280","article-title":"Defining the noninferiority margin and analysing noninferiority: An overview","volume":"83","author":"Althunian","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"10.25259\/IJMR_2458_2025\/ref-26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4103\/0378-6323.51258","article-title":"Scoring systems in acne vulgaris","volume":"75","author":"Adityan","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"10.25259\/IJMR_2458_2025\/ref-27","first-page":"40","article-title":"A comprehensive critique and review of published measures of acne severity","volume":"9","author":"Agnew","year":"2016","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ijd.14748","article-title":"A study comparing the clinical and hormonal profile of late onset and persistent acne in adult females","volume":"59","author":"Sardana","year":"2020","journal-title":"Int J Dermatol."},{"key":"10.25259\/IJMR_2458_2025\/ref-29","doi-asserted-by":"publisher","first-page":"e13974","DOI":"10.1111\/dth.13974","article-title":"A prospective study of anti-mullerian hormone and other ovarian and adrenal hormones in adult female acne","volume":"33","author":"Bansal","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.25259\/IJMR_2458_2025\/ref-31","article-title":"Using Cliff\u2019s Delta as a non-parametric effect size measure: An accessible web app and R tutorial","volume":"29","author":"Meissel","year":"2024","journal-title":"Pract Assess Res Eval."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/continuous-alternate-day-vs-intermittent-daily-fixed-doses-of-oral-isotretinoin-in-grade-2-acne-vulgaris\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/continuous-alternate-day-vs-intermittent-daily-fixed-doses-of-oral-isotretinoin-in-grade-2-acne-vulgaris\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:43:54Z","timestamp":1781113434000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/continuous-alternate-day-vs-intermittent-daily-fixed-doses-of-oral-isotretinoin-in-grade-2-acne-vulgaris\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":28,"alternative-id":["10.25259\/IJMR_2458_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2458_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"article-number":"731"}}